Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 5,918
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
ERINAH MUDONDO -
ID:
Liquidity management practices and Financial performance of banking institution in Kampala metropolitan - Uganda
REFNo: SS2872ES

To establish the influence of liquidity risk on the financial performance of banking institutions in Kampala Metropolitan.,To investigate the influence of liquidity management practices on financial performance of banking institutions in Kampala Metropolitan, Uganda.,
 Uganda 2024-08-28 18:17:15 2027-08-28 Social Science and Humanities Non-Clinical Trial Degree Award
Robert Downing George
ID: UNCST-2020-R014615
 A prospective, multi-centre study to evaluate the diagnostic sensitivity and specificity of the Determine Syphilis Advanced test.
REFNo: HS4648ES


The primary objective of this study is:
• To determine the diagnostic sensitivity and specificity of the Determine Syphilis Advanced test results using fingerstick capillary whole blood, venous whole blood, serum and venous plasma, when the test is performed by professional users.

The reference test will be Elecsys® Syphilis test (Roche). This test is an electrochemiluminescence immunoassay for the qualitative determination of total antibodies against Treponema pallidum. Samples with a negative Elecsys Syphilis result will be considered reference test-negative. Samples with a positive Elecsys Syphilis result will be confirmed by Treponema Pallidum Particle Agglutination (TPPA) testing. The TPPA result must be positive for the sample to be considered reference test-positive. Samples with a positive Elecsys Syphilis result but a negative or indeterminate TPPA result will be considered indeterminate and excluded from the study analyses. Potential discrepant result resolution using the Abbott Architect i1000SR Syphilis chemiluminescent microparticle immunoassay may be conducted for study reference test-positive or reference test-negative samples with discrepant investigational test results. The results from potential discrepant result resolution testing will be presented as table footnotes only. In addition to these treponemal tests, non-treponemal RPR testing will also be conducted for the reference test-positive participants, and the results may be stratified also by RPR status. All discrepant specimens shall be repeated using the same lot of RDT, and then on all available lots and any variability noted.

Another primary study objective is to compare the performance of the Determine Syphilis Advanced test with two commercially available similar tests, to meet the regulatory requirements in Japan. These two commercially available tests will be the TPPA test (SERODIA-TPPA, Fujirebio, Japan) and the Determine Syphilis TP test (Abbott). This analysis will be performed using 60 reference test-positive samples and 60 reference test-negative samples. The testing will be performed using plasma.

One study secondary objective is to evaluate the usability through completion of a user experience questionnaire (healthcare and laboratory staff).

Another study secondary objective is to determine the stability of venous whole blood, serum and plasma samples for use with Determine Syphilis Advanced, after refrigeration of the venous whole blood, serum and plasma at 2-8 degrees Celsius during 7 days before testing.

 UK 2024-08-28 17:34:38 2027-08-28 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Hillary Agaba
ID:
Understanding experiences of participating in a farmer research network from multiple perspectives in the Agroecology - Landscape project in Eastern Uganda
REFNo: SS2707ES

Provide an overview of the diversity of experiences across the Collaborative Resilient Food Systems (CRFS) countries, and different projects within countries, in ESAf. ,Gain more understanding of how FRN groups have developed and are functioning from the perspectives of those involved, ,Document the experience of participating in Farmer Research network (FRN) from multiple perspectives: farmers, researchers, NGO field staff and extension workers;,
 Uganda 2024-08-28 17:32:34 2027-08-28 Social Science and Humanities Non-Clinical Trial Non-degree Award
Dennis Muhanguzi
ID: UNCST-2019-R001101
 Comparing the Diagnostic Performance of the Rapid Tick Exposure Test (RaTexT®) and Larval Packet Test [LPT] for Acaricide Resistance Management in Uganda
REFNo: NS843ES

The general objective of this study will be to determine the diagnostic performance of RaTexT® compared to larval packet technique, test a mobile application for its ability to capture acaricide resistance data generated by RaTexT® and transmit it to end users as dynamic maps of acaricide resistance as well as determine the gender roles that are likely to underpin successful RaTexT® introduction. The specific objectives of this acaricide study will be to determine:
i.Laboratory and field diagnostic performance [specificity, sensitivity, negative and positive predictive values] of RaTexT® when used to detect acaricide resistance in tick populations isolated from different agro-ecological zones of Uganda.
ii. Possibility of integrating RaTexT® -generated acaricide resistance | susceptibility data into a mobile phone app to allow end-users to create dynamic maps of acaricide resistance in different African ecologies.
iii.Gender-based drivers of successful introduction and sustainable utilisation of RaTexT®

 Uganda 2024-08-28 17:31:08 2027-08-28 Natural Sciences Non-Clinical Trial Non-degree Award
Ruth Namazzi
ID: UNCST-2020-R014305
 Zinc for Infection Prevention in Sickle cell anemia ZIPS-2
REFNo: HS4824ES

The primary objective of the study is to determine if zinc supplementation at 20mg daily is safe and efficacious at reducing all-cause infection in Ugandan children 1.00-4.99 years of age with SCA.Secondary objectives 1. To determine the incidence of adverse events requiring discontinuation of study drug in children ages 1-4.99 supplemented with 20mg of daily zinc vs placebo 2. To determine the incidence of stroke or death in children ages 1-4.99 supplemented with 20mg of daily zinc vs placebo 3. To determine the incidence of infections requiring hospitalization in children ages 1-4.99 supplemented with 20mg of daily zinc vs placebo 4. To determine the incidence of vaso-occlusive crises in children ages 1-4.99 supplemented with 20mg of daily zinc vs placebo 5. To determine the change in transcranial Doppler (TCD) velocity from enrollment to 6-month study endpoint in children ages 1-4.99 supplemented with 20mg of daily zinc vs placebo 6. To determine change in serum zinc deficiency status from enrollment to 6-month study endpoint in children ages 1-4.99 supplemented with 20mg of daily zinc vs placebo 7. To determine the incidence of serious adverse events in children ages 1-4.99 supplemented with 20mg of daily zinc vs placebo 8. To determine the incidence of adverse events in children ages 1-4.99 supplemented with 20mg of daily zinc vs placebo
Uganda 2024-08-28 17:29:12 2027-08-28 Medical and Health Sciences Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS